Babiloni Claudio, Pennica Alfredo, Del Percio Claudio, Noce Giuseppe, Cordone Susanna, Lopez Susanna, Berry Ketura, Muratori Chiara, Ferracuti Stefano, Roma Paolo, Correr Valentina, Di Campli Francesco, Gianserra Laura, Ciullini Lorenzo, Aceti Antonio, Soricelli Andrea, Teti Elisabetta, Viscione Magdalena, Limatola Cristina, Onorati Paolo, Capotosto Paolo, Andreoni Massimo
Department of Physiology and Pharmacology, University of Rome "La Sapienza", Rome, Italy; IRCCS S. Raffaele Pisana, Rome, Italy.
Infectious Diseases, Faculty of Medicine and Psychology, University of Rome "La Sapienza", Rome, Italy.
Neuroimage Clin. 2016 Jun 8;12:144-56. doi: 10.1016/j.nicl.2016.06.005. eCollection 2016.
Here we tested the effect of combined antiretroviral therapy (cART) on deviant electroencephalographic (EEG) source activity in treatment-naïve HIV individuals.
Resting state eyes-closed EEG data were recorded before and after 5 months of cART in 48 male HIV subjects, who were naïve at the study start. The EEG data were also recorded in 59 age- and sex-matched healthy subjects as a control group. Frequency bands of interest included delta, theta, alpha1, alpha2 and alpha3, based on alpha frequency peak specific to each individual. They also included beta1 (13-20 Hz) and beta2 (20-30 Hz). Low-resolution brain electromagnetic tomography (LORETA) estimated EEG cortical source activity in frontal, central, temporal, parietal, and occipital regions.
Before the therapy, the HIV group showed greater parietal delta source activity and lower spatially diffuse alpha source activity compared to the control group. Thus, the ratio of parietal delta and alpha3 source activity served as an EEG marker. The z-score showed a statistically deviant EEG marker (EEG +) in 50% of the HIV individuals before therapy (p < 0.05). After 5 months of cART, delta source activity decreased, and alpha3 source activity increased in the HIV subjects with EEG + (about 50% of them showed a normalized EEG marker).
This procedure detected a deviant EEG marker before therapy and its post-therapy normalization in naïve HIV single individuals.
The parietal delta/alpha3 EEG marker may be used to monitor cART effects on brain function in such individuals.
在此,我们测试了联合抗逆转录病毒疗法(cART)对初治HIV感染者异常脑电图(EEG)源活动的影响。
在48名男性HIV受试者中记录了cART治疗5个月前后静息状态闭眼EEG数据,这些受试者在研究开始时为初治患者。还记录了59名年龄和性别匹配的健康受试者的EEG数据作为对照组。感兴趣的频段包括δ波、θ波、α1波、α2波和α3波,基于每个个体特定的α频率峰值。它们还包括β1(13 - 20Hz)和β2(20 - 30Hz)。低分辨率脑电磁断层扫描(LORETA)估计额叶、中央、颞叶、顶叶和枕叶区域的EEG皮质源活动。
治疗前,与对照组相比,HIV组显示出更高的顶叶δ波源活动和更低的空间弥散性α波源活动。因此,顶叶δ波和α3波源活动的比值作为EEG标志物。z评分显示治疗前50%的HIV感染者存在统计学上异常的EEG标志物(EEG +)(p < 0.05)。cART治疗5个月后,EEG +的HIV受试者中,δ波源活动降低,α3波源活动增加(其中约50%显示EEG标志物正常化)。
该程序检测到初治HIV个体治疗前异常的EEG标志物及其治疗后正常化。
顶叶δ波/α3波EEG标志物可用于监测此类个体中cART对脑功能的影响。